Epigenetically programmed resistance to chemo- and immuno-therapies.

2区 医学 Q1 Medicine Advances in Cancer Research Pub Date : 2023-01-01 Epub Date: 2023-01-27 DOI:10.1016/bs.acr.2022.12.001
Reddick R Walker, Zainab Rentia, Katherine B Chiappinelli
{"title":"Epigenetically programmed resistance to chemo- and immuno-therapies.","authors":"Reddick R Walker,&nbsp;Zainab Rentia,&nbsp;Katherine B Chiappinelli","doi":"10.1016/bs.acr.2022.12.001","DOIUrl":null,"url":null,"abstract":"<p><p>Resistance to cancer treatments remains a major barrier in developing cancer cures. While promising combination chemotherapy treatments and novel immunotherapies have improved patient outcomes, resistance to these treatments remains poorly understood. New insights into the dysregulation of the epigenome show how it promotes tumor growth and resistance to therapy. By altering control of gene expression, tumor cells can evade immune cell recognition, ignore apoptotic cues, and reverse DNA damage induced by chemotherapies. In this chapter, we summarize the data on epigenetic remodeling during cancer progression and treatment that enable cancer cell survival and describe how these epigenetic changes are being targeted clinically to overcome resistance.</p>","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"158 ","pages":"41-71"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184181/pdf/nihms-1897571.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/bs.acr.2022.12.001","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Resistance to cancer treatments remains a major barrier in developing cancer cures. While promising combination chemotherapy treatments and novel immunotherapies have improved patient outcomes, resistance to these treatments remains poorly understood. New insights into the dysregulation of the epigenome show how it promotes tumor growth and resistance to therapy. By altering control of gene expression, tumor cells can evade immune cell recognition, ignore apoptotic cues, and reverse DNA damage induced by chemotherapies. In this chapter, we summarize the data on epigenetic remodeling during cancer progression and treatment that enable cancer cell survival and describe how these epigenetic changes are being targeted clinically to overcome resistance.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
对化疗和免疫疗法的表观遗传学程序性耐药性。
对癌症治疗的耐药性仍然是开发癌症治疗方法的主要障碍。尽管有希望的联合化疗和新型免疫疗法改善了患者的预后,但对这些治疗的耐药性仍知之甚少。对表观基因组失调的新见解显示了它如何促进肿瘤生长和对治疗的耐药性。通过改变基因表达的控制,肿瘤细胞可以逃避免疫细胞的识别,忽略凋亡线索,并逆转化疗诱导的DNA损伤。在本章中,我们总结了癌症进展和治疗过程中表观遗传学重塑的数据,这些数据使癌症细胞存活,并描述了这些表观遗传学变化如何在临床上被靶向以克服耐药性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Advances in Cancer Research
Advances in Cancer Research 医学-肿瘤学
CiteScore
10.00
自引率
0.00%
发文量
52
期刊介绍: Advances in Cancer Research (ACR) has covered a remarkable period of discovery that encompasses the beginning of the revolution in biology. Advances in Cancer Research (ACR) has covered a remarkable period of discovery that encompasses the beginning of the revolution in biology. The first ACR volume came out in the year that Watson and Crick reported on the central dogma of biology, the DNA double helix. In the first 100 volumes are found many contributions by some of those who helped shape the revolution and who made many of the remarkable discoveries in cancer research that have developed from it.
期刊最新文献
Hereditary diffuse gastric cancer. Mass spectrometry based biomarkers for early detection of HCC using a glycoproteomic approach. Targeting the super elongation complex for oncogenic transcription driven tumor malignancies: Progress in structure, mechanisms and small molecular inhibitor discovery. Targeting epigenetic regulation for cancer therapy using small molecule inhibitors. Collaborative Spirit Drives the Field of Tumor Glycobiology: A Preface to Special Volume on Cancer Glycobiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1